These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antithrombotic therapy for atrial fibrillation in hereditary hemorrhagic telangiectasia. Virk ZM; Richardson TL; Al-Samkari H J Thromb Thrombolysis; 2023 Aug; 56(2):355-359. PubMed ID: 37340288 [TBL] [Abstract][Full Text] [Related]
7. Safety of reduced or absent antithrombotic therapy after left atrial appendage closure in patients affected by hereditary hemorrhagic telangiectasia and atrial fibrillation. Pepe M; Suppressa P; Giuliano AF; Nestola PL; Bortone AS; DE Cillis E; Acquaviva T; Forleo C; Moscarelli M; Lenato GM; Sabbà C Minerva Cardiol Angiol; 2022 Oct; 70(5):537-544. PubMed ID: 33703853 [TBL] [Abstract][Full Text] [Related]
8. High Rates of Bleeding Complications among Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia in the United States. Brinjikji W; Wood CP; Lanzino G; Cloft HJ; Misra S; Kallmes DF; Kamath P; Pruthi RK; Krowka MJ; Swanson KL; Iyer VN Ann Am Thorac Soc; 2016 Sep; 13(9):1505-11. PubMed ID: 27387823 [TBL] [Abstract][Full Text] [Related]
9. Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry. Gaetani E; Agostini F; Giarretta I; Porfidia A; Di Martino L; Gasbarrini A; Pola R; On Behalf Of The Multidisciplinary Gemelli Hospital Group For Hht J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498318 [TBL] [Abstract][Full Text] [Related]
10. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Parambil JG; Gossage JR; McCrae KR; Woodard TD; Menon KVN; Timmerman KL; Pederson DP; Sprecher DL; Al-Samkari H Angiogenesis; 2022 Feb; 25(1):87-97. PubMed ID: 34292451 [TBL] [Abstract][Full Text] [Related]
11. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646 [TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Kjeldsen AD; Kjeldsen J Am J Gastroenterol; 2000 Feb; 95(2):415-8. PubMed ID: 10685743 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial. Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Longacre AV; Gross CP; Gallitelli M; Henderson KJ; White RI; Proctor DD Am J Gastroenterol; 2003 Jan; 98(1):59-65. PubMed ID: 12526937 [TBL] [Abstract][Full Text] [Related]
16. Antiplatelet and oral anticoagulant therapies in chronic hemodialysis patients: prescribing practices and bleeding risk. Collette C; Clerc-Urmès I; Laborde-Castérot H; Frimat L; Ayav C; Peters N; Martin A; Agrinier N; Thilly N Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):935-43. PubMed ID: 27133538 [TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia. Thompson KP; Sykes J; Chandakkar P; Marambaud P; Vozoris NT; Marchuk DA; Faughnan ME Orphanet J Rare Dis; 2022 Nov; 17(1):405. PubMed ID: 36344987 [TBL] [Abstract][Full Text] [Related]